Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment

Please cite this paper as: Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment. Experimental Dermatology 2010; 19: 754–756. Abstract:  To investigate whether specific markers for innate immunity would diminish with successful treatment in psoriasis, we analyzed lesional and non-lesional skin biopsies taken from patients with moderate to severe psoriasis during 12 weeks of treatment with etanercept in correlation with the clinical response. In the clinical responders (PASI reduction >50%), all markers (CD3, CD68, CD161, elastase, BDCA-2, TNF-α) showed a decline during treatment, indicating a pivotal role for innate immunity in the pathogenesis of psoriasis.